Abstract
In the context of an update on new drugs used in the characterization of functional receptors for 5-hydroxytryptamine (5-HT), a review such as this on 5-HT2 receptor agonists and antagonists needs to address the criteria currently used to classify these receptors, and to consider the validity of these criteria in the light of the relevant data available on functional actions. In particular, any evidence suggesting heterogeneity within this functional receptor classification needs to be evaluated, thus quantitative functional data obtained in vitro for several 5-HT2 receptor antagonists in a range of tissues containing 5-HT2 receptors have been considered in some detail. Comparisons have also been made with data obtained in ligand binding studies. The question of specificity has also been briefly considered, and some recently developed 5-HT2 receptor agonists and antagonists have been discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology25: 563–576.
Peroutka SJ, Snyder SH (1979): Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H] spiroperidol. Mol Pharmacol16: 687–699.
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981): Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sciences28: 1015–1022.
Feniuk W, Hare J, Humphrey PPA (1981): An analysis of the mechanism of 5-hydroxytryptamine-induced vasopressor responses in ganglion-blocked anaesthetized dogs. J Pharm Pharmacol33: 155–160.
Colpaert FC, Niemegeers CJE, Janssen PAJ (1982): A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther221: 206–214.
Glennon RA, Young R, Rosecrans JA (1983): Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol91: 189–196.
Friedman RL, Barrett RJ, Sanders-Bush E (1984): Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites. J Pharmacol Exp Ther 228: 628–635.
Tricklebank MD (1985): The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor. Trends Pharmacol Sci6: 403–407.
Roberts MHT, Davies M (1989): In vivo electrophysiology of receptor subtypes mediating the central nervous system actions of 5-hydroxytryptamine, pp. 70–76 in: Mylecharane EJ, Angus JA, de la Lande IS, Humphrey PPA (eds), Serotonin: Actions, Receptors, Pathophysiology. Proceedings of Satellite Symposium of the IUPHAR 10th International Congress of Pharmacology, Heron Island, 4–6 September 1987. London: Macmillan.
Davies MF, Deisz RA, Prince DA, Peroutka SJ (1987): Physiological and pharmacological characterization of the response of guinea pig neocortical neurons to serotonin. Soc Neurosci Abstracts 13:801.
Gurevich N, Wu PH, Carlen PL (1987): Complexities of serotonin and serotonin antagonist interactions measured intracellularly in hippocampal CA, neurons. Soc Neurosci Abstracts13: 1650.
Maura G, Roccatagliata E, Ulivi M, Raiteri M (1988): Serotonin-glutamate interaction in rat cerebellum: involvement of 5-HT1 and 5-HT2 receptors. Eur J Pharmacol145: 31–38.
Koenig JI, Gudelsky GA, Meltzer HY (1987): Stimulation of corticosterone and endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacol137: 1–8.
Lenahan SE, Seibel HR, Johnson JH (1987): Opiate-serotonin synergism stimulating luteinizing hormone release in estrogen-progesterone-primed ovariectomized rats: mediation by serotonin2 receptors. Endocrinology120: 1498–1502.
Meltzer HY, Simonovic M, Gudelsky GA (1983): Effects of pirenperone and ketan- serin on rat prolactin secretion in vivo and in vitro. Eur J Pharmacol92: 83–89.
Willoughby JO, Menadue MF, Liebelt H (1987): Activation of serotonin receptors in the medial basal hypothalamus stimulates growth hormone secretion in the unanaesthetized rat. Brain Res404: 319–322.
Willoughby JO, Menadue MF, Liebelt H (1988): Activation of 5-HT 1 serotonin receptors in the medial basal hypothalamus stimulates prolactin secretion in the unanaesthetized rat. Neuroendocrinology47: 83–87.
Heninger GR, Charney DS, Smith A (1987): Effects of serotonin receptor agonists and antagonists on neuroendocrine function in rhesus monkeys. Soc Neurosci Abstracts13: 801.
Leff P, Martin GR (1986): Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists? Br J Pharmacol88: 585–593.
Arunlakshana O, Schild HO (1959): Some quantitative uses of drug antagonists. Br J Pharmacol14: 48–58.
Bradley PB, Humphrey PPA, Williams RH (1983): Are vascular ‘D’ and ‘5-HT2’ receptors for 5-hydroxytryptamine the same? Br J Pharmacol79: 295 P.
Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981): Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.J Pharmacol Exp Ther218: 217–230.
Bradley PB, Humphrey PPA, Williams RH (1985): Tryptamine-induced vasoconstriction responses in rat caudal arteries are mediated predominantly via 5-hydroxytrypta- mine receptors. Br J Pharmacol84: 919–925.
Hicks PE, Langer SZ (1983): Antagonism by tetrahydro-ß-carboline of the vasoconstrictor responses to tryptamine in rat tail arteries. Eur J Pharmacol96: 145–149.
Marwood JF, Stokes GS (1983): Vascular smooth muscle serotonin and a-adrenocep- tors. Clin Exp Pharmacol Physiol10: 265–267.
Mecca TE, Webb RC (1984): Vascular responses to serotonin in steroid hypertensive rats. Hypertension6: 887–892.
Cohen ML, Mason N, Wiley KS, Fuller RW (1983): Further evidence that vascular serotonin receptors are of the 5HT2 type. Biochem Pharmacol32: 567–570.
Lemberger HF, Mason N, Cohen ML (1984): 5HT2 receptors in the rat portal vein: desensitization following cumulative serotonin addition. Life Sci 35: 71–77.
Doggrell SA (1987): The effects of drugs on the contractile responses of the rat portal vein to phenylephrine and 5-hydroxytryptamine. Clin Exp Pharmacol PhysiolSuppl. 10: 34–35.
Cohen ML, Schenck KW, Colbert W, Wittenauer L (1985): Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle. J Pharmacol Exp Ther232: 770–774.
Humphrey PPA, Feniuk W, Watts AD (1982): Ketanserin—a novel antihypertensive drug? J Pharm Pharmacol34: 541.
Feniuk W, Humphrey PPA, Perren MJ, Watts AD (1985): A comparison of 5- hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol86: 697–704.
Sutherland RMcD, Fishburn PA, Phillips CA, Mylecharane EJ (1989): The actions of ketanserin in smooth muscle preparations (in preparation).
Ichida S, Hayashi T, Terao M (1983): Selective inhibition by ketanserin and spiroperidol of 5-HT-induced myometrial contraction Eur J Pharmacol96: 155–158.
Van Nueten JM, Janssen PAJ, De Ridder W, Vanhoutte PM (1982): Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468). Eur J Pharmacol77: 281–287.
Cohen RA (1986): Contractions of isolated canine coronary arteries resistant to S2-serotonergic blockade. J Pharmacol Exp Ther237: 548–552.
Lemoine H, Kaumann AJ (1986): Allosteric properties of 5-HT2 receptors in tracheal smooth muscle. Naunyn-Schmiedebergs Arch Pharmacol333: 91–97.
Forster C, Whalley ET (1982): Analysis of the 5-hydroxytryptamine induced contraction of the human basilar arterial strip compared with the rat aortic strip in vitro. Naunyn-Schmiedebergs Arch Pharmacol319: 12–17.
Apperley E, Humphrey PPA, Levy GP (1976): Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br J Pharmacol58: 211–221.
Stollak JS, Furchgott RF (1983): Use of selective antagonists for determining the types of receptors mediating the actions of 5-hydroxytryptamine and tryptamine in the isolated rabbit aorta.J Pharmacol Exp Ther224: 215–221.
Apperley E, Feniuk W, Humphrey PPA, Levy GP (1980): Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol68: 215–224.
Black JW, Brazenor RM, Gerskowitch VP, Leff P (1983): The problem of insurmountable antagonism in 5-hydroxytryptamine receptor classification Br J Pharmacol80: 607 P.
Cohen ML, Fuller RW, Wiley KS (1981): Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle. J Pharmacol Exp Ther218: 421–425.
Maayani S, Wilkinson CW, Stollak JS (1984): 5-hydroxytryptamine receptor in rabbit aorta: characterization by butyrophenone analogs. J Pharmacol Exp Ther 229: 346–350.
Clancy BM, Maayani S (1985): 5-hydroxytryptamine receptor in isolated rabbit aorta: characterization with tryptamine analogs. J Pharmacol Exp Ther 233: 761–769.
Black JL, French RJ, Mylecharane EJ (1981): Receptor mechanisms for 5-hydroxytryptamine in rabbit arteries. Br J Pharmacol74: 619–626.
Wrigglesworth SJ (1983): Heterogeneity of 5-hydroxytryptamine receptors in the rat uterus and stomach strip. Br J Pharmacol80: 691–697.
Cohen ML, Fuller RW, Kurz KD (1983): LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther227: 327–332.
Ben-Harari RR, Dalton B, Kaplan J, Maayani S (1987): Kinetic characterization of the response to 5-hydroxytryptamine in airway and vascular tissues. Soc Neurosci Abstracts13: 343.
Fong I, Philips CA, Mylecharane EJ (1987). 5-Hydroxytryptamine receptor subtypes in rabbit common carotid artery, guinea-pig trachea and rat stomach fundus preparations. Clin Exp Pharmacol Physiol Suppl. 11:189.
Leff P, Martin GR, Morse JM (1987): Differential classification of vascular smooth muscle and endothelial cell 5-HT receptors by use of tryptamine analogues. Br J Pharmacol91: 321–331.
Kaumann AJ (1983): Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5-HT2 receptors. Naunyn-Schmiedebergs Arch Pharmacol323: 149–154.
Frenken M, Kaumann AJ (1984): Interaction of ketanserin and its metabolite ketanserinol with 5-HT2 receptors in pulmonary and coronary arteries of calf. Naunyn- Schmiedebergs Arch Pharmacol326: 334–339.
Kaumann AJ, Frenken M (1985). A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptors. Naunyn-Schmiedebergs Arch Pharmacol328: 295–300.
Engel G, Hoyer D, Kalkman H, Wick MB (1985): Pharmacological similarity between the 5-HT-D-receptor on the guinea-pig ileum and the 5-HT2 binding site. Br J Pharmacol84: 106 P.
Eccles NK, Grimmer AJ, Leathard HL (1981): Action of ketanserin, a new 5-hydroxytryptamine antagonist, on human isolated blood vessels. Br J Pharmacol 74: 83IP–832P.
Müller-Schweinitzer E (1984): Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn-Schmiedebergs Arch Pharmacol327: 299–303.
Docherty JR, Hyland L (1986): An examination of 5-hydroxytryptamine receptors in human saphenous vein. Br J Pharmacol89: 77–81.
Clineschmidt BV, Reiss DD, Pettibone DJ, Robinson JL (1985): Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. J Pharmacol Exp Ther235: 696–708.
McGrath JC, MacLennan SJ, Stuart-Smith K (1985): Characterization of the receptor mediating contraction of human umbilical artery by 5-hydroxytryptamine. Br J Pharmacol84: 199–202.
McGrath JC, MacLennan SJ (1986): Oxygen modifies the potency of 5-HT, and of 5-HT antagonists, in human umbilical artery (HUA). Br J Pharmacol88: 320 P.
MacLennan SJ, McGrath JC (1986): Evidence for “5-HT1-like” receptors in human umbilical artery (HUA). Br J Pharmacol89: 587 P.
Tuncer M, Dogan N, Oktay S, Kayaalp SO (1985): Receptor mechanisms for 5-hydroxytryptamine in isolated human umbilical artery and vein. Arch Int Pharmaco- dyn Ther276: 17–27.
Brazenor RM, Angus JA (1981): Ergometrine contracts isolated coronary arteries by a serotonergic mechanism: no role for alpha adrenoceptors. J Pharmacol Exp Ther218: 530–536.
Brazenor RM, Angus JA (1982): Actions of serotonin antagonists on dog coronary artery. Eur J Pharmacol81: 569–576.
Porquet M-F, Pourrias B, Santamaria R (1982): Effects of 5-hydroxytryptamine on canine isolated coronary arteries. Br J Pharmacol75: 305–310.
Frenken M, Kaumann AJ (1985): Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions of large coronary arteries of dog. Naunyn- Schmiedebergs Arch Pharmacol328: 301–303.
Houston DS, Vanhoutte PM (1988): Comparison of serotonergic receptor subtypes on the smooth muscle and endothelium of the canine coronary artery. J Pharmacol Exp Ther244: 1–10.
Engel G, Göthert M, Müller-Schweinitzer E, Schlicker E, Sistonen L, Stadler PA (1983): Evidence for common pharmacological properties of [3H]-5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn-Schmiede- bergs Arch Pharmacol324: 116–124.
Kilbinger H, Pfeuffer-Friedrich I (1985): Two types of receptors for 5-hydroxytryptamine on the cholinergic nerves of the guinea-pig myenteric plexus. Br J Pharmacol85: 529–539.
Molderings GJ, Fink K, Schlicker E, Gothert M (1987): Inhibition of noradrenaline release via presynaptic 5-HT1B receptors of the rat vena cava. Naunyn-Schmiedebergs Arch Pharmacol336: 245–250.
Müller-Schweinitzer E, Engel G (1983): Evidence for mediation by 5-HT2 receptors of 5-hydroxytryptamine-induced contraction of canine basilar artery. Naunyn-Schmiede- bergsArch Pharmacol324: 287–292.
Peroutka SJ, Noguchi M, Tolner DJ, Allen GS (1983): Serotonin-induced contraction of canine basilar artery: mediation by 5-HT, receptors. Brain Res259: 327–330.
Peroutka SJ, Kuhar MJ (1984): Autoradiographic localization of 5-HT1, receptors to human and canine basilar arteries. Brain Res310: 193–196.
Peroutka SJ, Huang S, Allen GS (1986): Canine basilar artery contractions mediated by 5-hydroxytryptamine1A receptors. J Pharmacol Exp Ther237: 901–906.
Cohen ML, Colbert WE (1986): Relationship between receptors mediating serotonin (5-HT) contractions in the canine basilar artery to 5-HT1, 5-HT2 and rat stomach fundus 5-HT receptors. J Pharmacol Exp Ther237: 713–718.
Taylor EW, Duckies SP, Nelson DL (1986): Dissociation constants of serotonin agonists in the canine basilar artery correlate to Ki values at the 5-HT1A binding site. J Pharmacol Exp Ther236: 118 - 125.
Frenken M, Kaumann AJ (1986): Surmountable antagonism by ketanserin of 5-hydroxytryptamine-induced contractions in dog basilar artery. Br J Pharmacol89: 550 P.
Peroutka SJ, Lebovitz RM, Snyder SH (1981): Two distinct central serotonin receptors with different physiological functions. Science212: 827–829.
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982): [3H] Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites: binding properties, brain distribution, and functional role. Mol Pharmacol 21: 301–314.
Martin LL, Sanders-Bush E (1982): Comparison of the pharmacological characteristics of 5HT1 and 5HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn-Schmiedebergs Arch Pharmacol321: 165–170.
Cohen ML, Wittenauer LA (1985): Relationship between serotonin and tryptamine receptors in the rat stomach fundus. J Pharmacol Exp Ther233: 75–79.
Pazos A, Hoyer D, Palacios JM (1985): Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. Eur J Pharmacol106: 531–538.
Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (1986): Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedebergs Arch Pharmacol332: 1–7.
Schotte A, Maloteaux JM, Laduron PM (1983): Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res276: 231–235.
McBride PA, Mann JJ, McEwen B, Biegon A (1983): Characterization of serotonin binding sites on human platelets. Life Sci33: 2033–2041.
Leysen JE, de Chaffoy de Courcelles D, De Clerck F, Niemegeers CJE, Van Nueten JM (1984): Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacology23: 1493–1501.
Ichida S, Hayashi T, Kita T, Murakami T (1985): Estradiol-induced increase of specific [3H] ketanserin binding sites on rat uterine membranes. Eur J Pharmacol 108: 257–264.
Shannon, M, Battaglia G, Glennon RA, Titeler M (1984): 5-HT, and 5-HT2 binding properties of the hallucinogen l-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol 102:23–29.
Lyon RA, Titeler M, Glennon RA (1987): LSD and phenylisopropylamine hallucinogen interactions with multiple radiolabeled brain serotonin receptors. Soc Neurosci Abstracts13: 1183.
Wang SS, Peroutka SJ (1987): 2,5-Dimethoxy-4-bromoamphetamine (DOB) interactions with 5-HT receptor subtypes. Soc Neurosci Abstracts13: 1237.
Schechter LE, Simansky KJ (1987): l-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane HC1 (DOI), a selective 5-HT2 agonist, exerts an anorexic action in rats that is prevented by LY53857, a selective 5-HT2 antagonist. Soc Neurosci Abstracts13: 1339.
McCall RB, Harris LT (1988): 5-HT2 receptor agonists increase spontaneous sympathetic nerve discharge. Eur J Pharmacol 151:113–116.
Glennon RA, Seggel MR, Soine WH, Davis KH, Lyon RA, Titeler M (1987): [125DOI]: a new radiolabel for 5-HT2 serotonin sites. Soc. Neurosci Abstracts13: 1181.
Nelson DL, Killam AL, Lambert G, Nikam SS, Week B, Martin AR (1987): Structure-activity relationships of a series of tetrahydropyridylindoles at serotonin1A and serotonin2 receptors. Soc Neurosci Abstracts13: 1236.
Hirata M, Imamoto T, Shibouta Y, Kurihara Y, Kito G, Sugihara H (1986): A selective S2-serotonin blocker, CV-5197, a benzoxathiepin analog. Blood Vessels23: 76.
Blackburn TP, Cox B, Pearce RJ, Thornber CW (1987): In vivo pharmacology of ICI 169,369—a new 5-HT2 antagonist. Br J Pharmacol90: 256 P.
Blackburn TP, Thornber CW, Pearce RJ, Cox B (1988): In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist. Eur J Pharmacol150: 247–256.
Blackburn TP, Cox B, Grant TL, Growcott JW (1987): ICI 169369 is an antagonist of 5-HT in tissues claimed to contain 5-HT1A and 5-HT1c receptors. Soc Neurosci Abstracts13: 801.
Cummings SA, Groszmann RJ, Kaumann AJ (1986): Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol89: 501–513.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mylecharane, E.J. (1990). Agonists and antagonists of 5-HT2 receptors. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_7
Download citation
DOI: https://doi.org/10.1007/978-94-009-0479-8_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6701-0
Online ISBN: 978-94-009-0479-8
eBook Packages: Springer Book Archive